Life ScienceCompany
Paratek Pharmaceuticals M&A Summary
Paratek Pharmaceuticals has acquired 2 companies of its own, including 1 in the last 5 years.
Paratek Pharmaceuticals’ largest acquisition to date was in 2025, when it acquired OptiNose for $330M. Paratek Pharmaceuticals has acquired in 2 different US states. The Company’s most targeted sectors include medical products (100%).
Paratek Pharmaceuticals Ownership
Who owns Paratek Pharmaceuticals?
Paratek Pharmaceuticals is owned by Gurnet Point Capital and Novo Holdings A/S. It was acquired on June 6, 2023.
Is Paratek Pharmaceuticals PE-backed?
Yes. Paratek Pharmaceuticals is owned by private equity investors Gurnet Point Capital and Novo Holdings A/S.
Was Paratek Pharmaceuticals formerly PE-backed?
Yes. Paratek Pharmaceuticals was formerly owned by 1 private investor.
Paratek Pharmaceuticals Business Overview
Where is Paratek Pharmaceuticals headquartered?
Paratek Pharmaceuticals is headquartered in King of Prussia, Pennsylvania.
What is Paratek Pharmaceuticals’ revenue?
Paratek Pharmaceuticals disclosed revenue of 47M USD for 2020 and 17M USD for 2019.
How many employees does Paratek Pharmaceuticals have?
Paratek Pharmaceuticals has 101 employees.
What sector is Paratek Pharmaceuticals in?
Paratek Pharmaceuticals is a life science company.
When was Paratek Pharmaceuticals founded?
Paratek Pharmaceuticals was founded in 1996.
M&A Summary
-
M&A Total Activity2
- M&A Buy Activity2
- Total Sectors Invested 1
- Total Countries Invested 1
- M&A Advisors 2
Unlimited Searches
